The purpose of this publication is to report a child with choroidal metastasis from a primary lung carcinoid tumor treated with 125-iodine plaque brachytherapy while achieving complete tumor regression. A 15-year-old girl with a history of stage IV lung carcinoid tumor developed painless progressive visual loss in her right eye. Ophthalmological exam documented a unilateral solitary large choroidal mass with complete exudative retinal detachment. Planned palliative treatment with plaque brachytherapy was performed utilizing a total dose of 45 Gy to the tumor apex. No tumor regression was noted after 6 months of follow-up. Ten months after primary therapy, re-treatment with a total dose of 90 Gy to the tumor apex was performed due to tumor progression. Complete regression was achieved after secondary treatment without evidence of recurrence after 18 months of follow-up. In conclusion, high-dose plaque brachytherapy may induce complete tumor regression in select adolescent patients with choroidal metastasis from lung carcinoid tumor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613577 | PMC |
http://dx.doi.org/10.1159/000519045 | DOI Listing |
Cornea
October 2024
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
Purpose: The purpose of this study was to report the management of chemoimmunotherapy-resistant ocular surface squamous neoplasia (OSSN) with iodine-125 (I-125) brachytherapy.
Methods: A 36-year-old man presented to the clinic with biopsy-proven OSSN that covered ∼70% of the corneal surface and extended to the 6 o'clock position of the inferior limbus of the OS. The visual acuity was 20/20 in the OD and 20/40 in the affected OS.
Indian J Ophthalmol
January 2025
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Objective: To study the prevalence, clinical presentation, treatment, and follow-up of ocular (dermal) melanocytosis (ODM) and its association with choroidal melanoma (CM) in Asian Indian patients.
Methods: This was a retrospective case series of patients with ODM conducted in a quaternary eye care center.
Results: Of the total 1.
J Contemp Brachytherapy
October 2024
Department of Radiation Oncology, East Carolina University, Greenville, North Carolina, USA.
Purpose: To investigate sensitivity of contributing factors to heterogeneity corrections in ocular brachytherapy using iodine-125 (I) Collaborative Ocular Melanoma Study (COMS) plaques.
Material And Methods: Using egs_brachy, Monte Carlo (MC) simulations were performed for I COMS plaques (model: IsoAid IAI-125A). Homogeneous dose (D) was estimated under the American Association of Physicists in Medicine Task Group-43 assumptions, with 85 Gy prescribed to a 5 mm depth.
Am J Ophthalmol
December 2024
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia PA. Electronic address:
Purpose: Uveal melanoma (UM) represents the most prevalent and aggressive intraocular malignancy in adults. This study examined the outcomes of patients diagnosed with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel LINAC-based frameless technique.
Design: Retrospective, interventional case series.
Appl Radiat Isot
December 2024
Department of Physics, Faculty of Science, University of Guilan, Rasht, Iran. Electronic address:
Uveal melanoma is the most common primary eye cancer with the highest incidence. BEBIG Ru/Rh ophthalmic plaques more used for the treatment of these eye malignancies, mainly malignancies with small to medium sizes. In this study, we evaluate dose distributions around a voxelized eye phantom due to CCA and CCB eye plaque using GATE code.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!